JRS_PHARMACIES_LIMITED - Accounts

Company registration number 07778576 (England and Wales)
JRS PHARMACIES LIMITED
T/A GRIFFITHS PHARMACY
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2021
PAGES FOR FILING WITH REGISTRAR
JRS PHARMACIES LIMITED
T/A GRIFFITHS PHARMACY
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 8
JRS PHARMACIES LIMITED
T/A GRIFFITHS PHARMACY
BALANCE SHEET
AS AT
30 SEPTEMBER 2021
30 September 2021
- 1 -
2021
2020
Notes
£
£
£
£
Fixed assets
Intangible assets
3
60,500
66,500
Tangible assets
4
47,161
42,056
107,661
108,556
Current assets
Stocks
35,838
48,241
Debtors
5
642,189
208,751
Cash at bank and in hand
116,214
329,599
794,241
586,591
Creditors: amounts falling due within one year
6
(514,411)
(428,886)
Net current assets
279,830
157,705
Total assets less current liabilities
387,491
266,261
Creditors: amounts falling due after more than one year
7
(58,355)
(85,435)
Provisions for liabilities
(1,320)
179
Net assets
327,816
181,005
Capital and reserves
Called up share capital
3,000
3,000
Profit and loss reserves
324,816
178,005
Total equity
327,816
181,005

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 30 September 2021 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

JRS PHARMACIES LIMITED
T/A GRIFFITHS PHARMACY
BALANCE SHEET (CONTINUED)
AS AT
30 SEPTEMBER 2021
30 September 2021
- 2 -
The financial statements were approved by the board of directors and authorised for issue on 27 September 2022 and are signed on its behalf by:
Jeffrey Wong
Director
Company Registration No. 07778576
JRS PHARMACIES LIMITED
T/A GRIFFITHS PHARMACY
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2021
- 3 -
1
Accounting policies
Company information

JRS Pharmacies Limited is a private company limited by shares incorporated in England and Wales. The registered office is The Copper Room, Deva City Office Park, Trinity Way, Manchester, M3 7BG. The business address of the company is 37 Welsh Road, Garden City, Deeside, Flintshire, CH5 2HU.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

 

 

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.3
Intangible fixed assets - goodwill
Acquired goodwill is written off in equal annual instalments over its estimated useful economic life of twenty years.
1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold improvements
0%
Fixtures, fittings & equipment
15% straight line and 33% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.5
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

JRS PHARMACIES LIMITED
T/A GRIFFITHS PHARMACY
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2021
1
Accounting policies
(Continued)
- 4 -

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.6
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.7
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.8
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

JRS PHARMACIES LIMITED
T/A GRIFFITHS PHARMACY
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2021
1
Accounting policies
(Continued)
- 5 -
Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.9
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.10
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax
Deferred taxation is provided in full in respect of taxation deferred by timing differences between the treatment of certain items for taxation and accounting purposes.  The deferred tax balance has not been discounted.
1.11
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.12
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

JRS PHARMACIES LIMITED
T/A GRIFFITHS PHARMACY
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2021
1
Accounting policies
(Continued)
- 6 -
1.13
Government grants

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

 

A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2021
2020
Number
Number
Total
20
20
3
Intangible fixed assets
Goodwill
£
Cost
At 1 October 2020 and 30 September 2021
120,000
Amortisation and impairment
At 1 October 2020
53,500
Amortisation charged for the year
6,000
At 30 September 2021
59,500
Carrying amount
At 30 September 2021
60,500
At 30 September 2020
66,500
JRS PHARMACIES LIMITED
T/A GRIFFITHS PHARMACY
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2021
- 7 -
4
Tangible fixed assets
Land and buildings
Plant and machinery etc
Total
£
£
£
Cost
At 1 October 2020
37,132
60,451
97,583
Additions
-
0
10,836
10,836
At 30 September 2021
37,132
71,287
108,419
Depreciation and impairment
At 1 October 2020
-
0
55,527
55,527
Depreciation charged in the year
-
0
5,731
5,731
At 30 September 2021
-
0
61,258
61,258
Carrying amount
At 30 September 2021
37,132
10,029
47,161
At 30 September 2020
37,132
4,924
42,056
5
Debtors
2021
2020
Amounts falling due within one year:
£
£
Trade debtors
177,055
163,704
Corporation tax recoverable
-
0
7,314
Other debtors
465,134
37,733
642,189
208,751
6
Creditors: amounts falling due within one year
2021
2020
£
£
Bank loans
27,080
37,706
Trade creditors
157,211
219,250
Corporation tax
12,262
-
0
Other taxation and social security
46,814
33,099
Other creditors
271,044
138,831
514,411
428,886

The bank loan falling due within one year of £17,080 (2020 - £16,377) is secured by a fixed an floating charge over all the assets and is held by Lloyds Bank Plc.

JRS PHARMACIES LIMITED
T/A GRIFFITHS PHARMACY
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2021
- 8 -
7
Creditors: amounts falling due after more than one year
2021
2020
£
£
Bank loans and overdrafts
58,355
85,435

The bank loan falling due after more than one year of £20,855 (2020: £37,935 ) is secured by a fixed and floating charge over all the assets and is held by Lloyds Bank Plc.

2021-09-302020-10-01false28 September 2022CCH SoftwareCCH Accounts Production 2022.200No description of principal activityJeffrey WongRichard GriffithsMr S Ahmed077785762020-10-012021-09-30077785762021-09-30077785762020-09-3007778576core:NetGoodwill2021-09-3007778576core:NetGoodwill2020-09-3007778576core:LandBuildings2021-09-3007778576core:OtherPropertyPlantEquipment2021-09-3007778576core:LandBuildings2020-09-3007778576core:OtherPropertyPlantEquipment2020-09-3007778576core:CurrentFinancialInstrumentscore:WithinOneYear2021-09-3007778576core:CurrentFinancialInstrumentscore:WithinOneYear2020-09-3007778576core:Non-currentFinancialInstrumentscore:AfterOneYear2021-09-3007778576core:Non-currentFinancialInstrumentscore:AfterOneYear2020-09-3007778576core:CurrentFinancialInstruments2021-09-3007778576core:CurrentFinancialInstruments2020-09-3007778576core:ShareCapital2021-09-3007778576core:ShareCapital2020-09-3007778576core:RetainedEarningsAccumulatedLosses2021-09-3007778576core:RetainedEarningsAccumulatedLosses2020-09-3007778576bus:Director12020-10-012021-09-3007778576core:Goodwill2020-10-012021-09-3007778576core:LeaseholdImprovements2020-10-012021-09-3007778576core:FurnitureFittings2020-10-012021-09-30077785762019-10-012020-09-3007778576core:NetGoodwill2020-09-3007778576core:NetGoodwill2020-10-012021-09-3007778576core:LandBuildings2020-09-3007778576core:OtherPropertyPlantEquipment2020-09-30077785762020-09-3007778576core:LandBuildings2020-10-012021-09-3007778576core:OtherPropertyPlantEquipment2020-10-012021-09-3007778576core:WithinOneYear2021-09-3007778576core:WithinOneYear2020-09-3007778576core:Non-currentFinancialInstruments2021-09-3007778576core:Non-currentFinancialInstruments2020-09-3007778576bus:PrivateLimitedCompanyLtd2020-10-012021-09-3007778576bus:SmallCompaniesRegimeForAccounts2020-10-012021-09-3007778576bus:FRS1022020-10-012021-09-3007778576bus:AuditExemptWithAccountantsReport2020-10-012021-09-3007778576bus:Director22020-10-012021-09-3007778576bus:Director32020-10-012021-09-3007778576bus:FullAccounts2020-10-012021-09-30xbrli:purexbrli:sharesiso4217:GBP